SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/07/23 Akoya Biosciences, Inc. 10-K 12/31/22 103:14M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.89M 7: EX-4.2 Instrument Defining the Rights of Security Holders HTML 46K 2: EX-10.22 Material Contract HTML 1.35M 3: EX-23.1 Consent of Expert or Counsel HTML 27K 4: EX-31.1 Certification -- §302 - SOA'02 HTML 34K 5: EX-31.2 Certification -- §302 - SOA'02 HTML 34K 6: EX-32.1 Certification -- §906 - SOA'02 HTML 30K 13: R1 Document and Entity Information HTML 97K 14: R2 Consolidated Balance Sheets HTML 148K 15: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K 16: R4 Consolidated Statements of Operations HTML 126K 17: R5 Consolidated Statements of Comprehensive Loss HTML 51K 18: R6 Consolidated Statements of Redeemable Convertible HTML 108K Preferred Stock and Stockholders Equity 19: R7 Consolidated Statements of Cash Flows HTML 138K 20: R8 The company and basis of presentation HTML 37K 21: R9 Summary of significant accounting policies HTML 106K 22: R10 Significant risks and uncertainties including HTML 32K business and credit concentrations 23: R11 Fair value of financial instruments HTML 178K 24: R12 Property and equipment, net HTML 67K 25: R13 Intangible assets and goodwill HTML 86K 26: R14 Accrued expenses and other current liabilities HTML 43K 27: R15 Debt HTML 59K 28: R16 Stockholder's equity (Deficit) HTML 37K 29: R17 Stock compensation plans HTML 123K 30: R18 Employee stock purchase plan HTML 126K 31: R19 Income taxes HTML 137K 32: R20 Commitments and contingencies HTML 31K 33: R21 Net loss per share attributable to common HTML 57K stockholders 34: R22 Segments HTML 62K 35: R23 Related party transactions HTML 31K 36: R24 Leases HTML 141K 37: R25 Subsequent events HTML 30K 38: R26 Summary of significant accounting policies HTML 178K (Policies) 39: R27 Summary of significant accounting policies HTML 48K (Tables) 40: R28 Fair value of financial instruments (Tables) HTML 183K 41: R29 Property and equipment, net (Tables) HTML 67K 42: R30 Intangible assets and goodwill (Tables) HTML 87K 43: R31 Accrued expense and other current liabilities HTML 42K (Tables) 44: R32 Debt (Tables) HTML 55K 45: R33 Stock compensation plans (Tables) HTML 123K 46: R34 Income taxes (Tables) HTML 137K 47: R35 Net loss per share attributable to common HTML 57K stockholders (Tables) 48: R36 Segments (Tables) HTML 56K 49: R37 Leases (Tables) HTML 142K 50: R38 The company and basis of presentation - Initial HTML 54K public offering (Details) 51: R39 The company and basis of presentation - Liquidity HTML 38K and going concern (Details) 52: R40 Summary of significant accounting policies - HTML 30K Accounts receivable (Details) 53: R41 Summary of significant accounting policies - HTML 33K Intangible assets (Details) 54: R42 Summary of significant accounting policies - HTML 57K Service and Other Revenue and Disaggregation of Revenue (Details) 55: R43 Summary of significant accounting policies - HTML 31K Capitalized software development costs (Details) 56: R44 Summary of significant accounting policies - HTML 30K Advertising expenses (Details) 57: R45 Summary of significant accounting policies - HTML 35K Deferred offering costs and stock-based compensation (Details) 58: R46 Significant risks and uncertainties including HTML 37K business and credit concentrations (Details) 59: R47 Fair value of financial instruments (Details) HTML 60K 60: R48 Fair value of financial instruments - Cash, cash HTML 43K equivalents and marketable securities (Details) 61: R49 Fair value of financial instruments - Innovatus HTML 40K Term Loan (Details) 62: R50 Fair value of financial instruments - Recurring HTML 49K Basis Unobservable (Details) 63: R51 Property and equipment, net (Details) HTML 54K 64: R52 Property and equipment, net - Demo inventory HTML 37K (Details) 65: R53 Intangible assets and goodwill (Details) HTML 62K 66: R54 Intangible assets and goodwill - Amortization HTML 44K expense related to identifiable intangible assets in future periods (Details) 67: R55 Intangible assets and goodwill - Goodwill balance HTML 30K (Details) 68: R56 Accrued expenses and other current liabilities HTML 39K (Details) 69: R57 Debt - Term Loan Agreements (Details) HTML 84K 70: R58 Debt - Debt components (Details) HTML 43K 71: R59 Debt - Debt maturities (Details) HTML 41K 72: R60 Debt - Sale of Series D Preferred Stock (Details) HTML 35K 73: R61 Stockholder's equity (Deficit) (Details) HTML 53K 74: R62 Stock compensation plans - 2021 Equity Incentive HTML 36K Plan (Details) 75: R63 Stock compensation plans - 2015 Equity Incentive HTML 38K Plan (Details) 76: R64 Stock compensation plans - Summary of option HTML 69K activity (Details) 77: R65 Stock compensation plans - Stock Options (Details) HTML 50K 78: R66 Stock compensation plans - Restricted Stock Units HTML 55K (Details) 79: R67 Stock compensation plans - Stock-based HTML 46K compensation expense and unrecognized compensation cost (Details) 80: R68 Employee stock purchase plan (Details) HTML 41K 81: R69 Income taxes (Details) HTML 52K 82: R70 Income taxes - Components of net income (Loss) HTML 38K Before Income Taxes (Details) 83: R71 Income taxes - Income tax provision (Details) HTML 51K 84: R72 Income taxes - Reconciliation between income tax HTML 52K benefit and expected tax benefit at the statutory rate (Details) 85: R73 Income taxes - Significant components of net HTML 64K deferred tax liability (Details) 86: R74 Income taxes - Rollforward of uncertain tax HTML 34K positions related to research and development tax credits (Details) 87: R75 Commitments and contingencies - License Agreements HTML 38K (Details) 88: R76 Net loss per share attributable to common HTML 66K stockholders (Details) 89: R77 Net loss per share attributable to common HTML 38K stockholders - Antidilutive shares (Details) 90: R78 Segments (Details) HTML 46K 91: R79 Segments - Revenue (Details) HTML 43K 92: R80 Related party transactions (Details) HTML 45K 93: R81 Leases - Adoption of ASU 2016-02 (Details) HTML 110K 94: R82 Leases - Office and warehouse leases (Details) HTML 51K 95: R83 Leases - Lease cost classification (Details) HTML 40K 96: R84 Leases - Future minimum commitments under HTML 47K operating leases (Details) 97: R85 Leases - Future minimum commitments under HTML 40K financing leases (Details) 98: R86 Leases - Weighted-average remaining lease term, HTML 47K incremental borrowing rate, and supplemental cash flow information (Details) 101: XML IDEA XML File -- Filing Summary XML 193K 99: XML XBRL Instance -- akya-20221231x10k_htm XML 2.61M 100: EXCEL IDEA Workbook of Financial Reports XLSX 187K 9: EX-101.CAL XBRL Calculations -- akya-20221231_cal XML 245K 10: EX-101.DEF XBRL Definitions -- akya-20221231_def XML 737K 11: EX-101.LAB XBRL Labels -- akya-20221231_lab XML 1.63M 12: EX-101.PRE XBRL Presentations -- akya-20221231_pre XML 1.25M 8: EX-101.SCH XBRL Schema -- akya-20221231 XSD 202K 102: JSON XBRL Instance as JSON Data -- MetaLinks 547± 868K 103: ZIP XBRL Zipped Folder -- 0001558370-23-002954-xbrl Zip 1.40M
Exhibit 4.2
DESCRIPTION OF CAPITAL STOCK
REGISTERED PURSUANT TO SECTION 12
OF THE SECURITIES EXCHANGE ACT OF 1934
The following description of the common stock of Akoya Biosciences, Inc. (“we,” “us” and “our”) is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”), our Amended and Restated Bylaws (“Bylaws”) and our Amended and Restated Investors’ Rights Agreement (“Investors’ Rights Agreement “). This description also summarizes relevant provisions of General Corporation Law of the State of Delaware (the “DGCL”). We encourage you to read these materials for additional information.
General
Our authorized capital stock consists of 500,000,000 shares of common stock, $0.00001 par value per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated.
Common Stock
The holders of our common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. The holders of our common stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our board of directors out of funds legally available, subject to preferences that may be applicable to preferred stock, if any, then outstanding. In the event of a liquidation, dissolution or winding up of our company, the holders of common stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. Our common stock has no preemptive or conversion rights or other subscription rights or redemption or sinking fund provisions.
Preferred Stock
Our Certificate of Incorporation authorizes our board of directors to establish one or more series of preferred stock (including convertible preferred stock). Unless required by law or any stock exchange, the authorized shares of preferred stock will be available for issuance without further action by the holders of our common stock. Our board of directors will be able to determine, with respect to any series of preferred stock, the powers (including voting powers), preferences and relative, participating, optional or other special rights, and the qualifications, limitations, or restrictions thereof. No shares of preferred stock have been issued or are outstanding as of the date of the filing of the Annual Report on Form 10-K of which this Description forms a part, and we have no present plan to issue any shares of preferred stock.
Anti-Takeover Matters in our Governing Documents and Under Delaware Law
Our Certificate of Incorporation and our Bylaws contain, and the DGCL contains, provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control, and enhance the ability of our board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an antitakeover effect and may delay, deter, or prevent a merger or acquisition by means of a tender offer, a proxy contest, or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders.
Authorized But Unissued Capital Stock
The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more
difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger, or otherwise.
Classified Board of Directors
Our Certificate of Incorporation provides that our board of directors be divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. Directors may only be removed from our board of directors for cause by the affirmative vote of at least 662∕3% of the voting power of all of our then-outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. In addition, our Certificate of Incorporation provides that, subject to the rights granted to one or more series of preferred stock then outstanding, any newly created directorship on the board of directors that results from an increase in the number of directors and any vacancies on our board of directors will be filled only by the affirmative vote of a majority of the remaining directors, even if less than a quorum, or by a sole remaining director. A director chosen to fill a position resulting from an increase in the number of directors will hold office until the next election of the director’s class and until the director’s successor is duly elected and qualified, or until the director’s earlier death, resignation or removal. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of us or changes in our management.
Delaware Anti-Takeover Law
We are subject to Section 203 of the DGCL, which is an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date that the person became an interested stockholder, unless the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a business combination includes a merger, asset or stock sale, or another transaction resulting in a financial benefit to the interested stockholder. Generally, an interested stockholder is a person who, together with affiliates and associates, owns 15% or more of the corporation’s outstanding voting stock or is the corporation’s affiliate or associate and was the owner of 15% or more of the corporation’s outstanding voting stock at any time within the three-year period immediately before the date of determination. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our board, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by stockholders.
No Cumulative Voting
Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. Our Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our stock entitled to vote generally in the election of directors are able to elect all of our directors.
Special Stockholder Meetings
Our Certificate of Incorporation provides that special meetings of our stockholders may be called at any time only by or at the direction of the board of directors, the chair of the board of directors or our Chief Executive Officer. Our Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management.
Director Nominations and Stockholder Proposals
Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder’s notice must be received at our principal executive offices not less than
90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. Our Bylaws also specify requirements as to the form and content of a stockholder’s notice. Our Bylaws allow the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to influence or obtain control.
Stockholder Action by Written Consent
Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice, and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the certificate of incorporation provides otherwise. Our Certificate of Incorporation precludes stockholder action by written consent.
Amendment of Certificate of Incorporation or Bylaws
The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our Bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our Certificate of Incorporation described above.
The foregoing provisions of our Certificate of Incorporation and our Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares of common stock that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management or delaying or preventing a transaction that might benefit you or other minority stockholders.
Exclusive Forum
Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware be the sole and exclusive forum for: (1) any derivative action or proceeding brought on behalf of our company, (2) any action asserting a claim of breach of fiduciary duty owed by any director, officer, agent, or other employee or stockholder of our company to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim governed by the internal affairs doctrine, in each case subject to such Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. It will further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolutions of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the “Securities Act”). The exclusive forum clauses described above shall not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended or any other claim for which the federal courts have exclusive jurisdiction. Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of
discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in such action. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Certificate of Incorporation.
Limitations of Liability and Indemnification
The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties, subject to certain exceptions. Our Certificate of Incorporation includes a provision that eliminates the personal liability of directors for monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions is to eliminate the rights of us and our stockholders, through stockholders’ derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation does not apply to any breaches of the director’s duty of loyalty, any acts or omissions not in good faith or that involve intentional misconduct or knowing violation of law, any authorization of dividends or stock redemptions or repurchases paid or made in violation of the DGCL, or for any transaction from which the director derived an improper personal benefit.
Our Bylaws generally rovide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also are expressly authorized to carry directors’ and officers’ liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.
The limitation of liability, indemnification and advancement provisions in our Certificate of Incorporation and our Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.
We have entered into indemnification agreements with each of our directors and executive officers. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC such indemnification is against public policy and is therefore unenforceable.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent’s address is 6201 15th Avenue Brooklyn, New York 11219.
Listing
Our common stock is listed on Nasdaq under the symbol “AKYA.”
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/14/24 Akoya Biosciences, Inc. 10-Q 3/31/24 95:8.6M Toppan Merrill Bridge/FA 3/05/24 Akoya Biosciences, Inc. 10-K 12/31/23 106:12M Toppan Merrill Bridge/FA 3/05/24 Akoya Biosciences, Inc. S-8 3/05/24 4:74K Toppan Merrill/FA 6/09/23 Akoya Biosciences, Inc. 424B5 1:541K Toppan Merrill/FA 6/07/23 Akoya Biosciences, Inc. 424B5 1:541K Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/07/22 Akoya Biosciences, Inc. S-3 7:2.2M Toppan Merrill/FA 8/09/22 Akoya Biosciences, Inc. 10-Q 6/30/22 91:10M Toppan Merrill Bridge/FA 6/02/22 Akoya Biosciences, Inc. 8-K:1,2,9 6/01/22 11:1.2M Toppan Merrill/FA 3/29/22 Akoya Biosciences, Inc. 8-K:1,9 3/23/22 11:280K Toppan Merrill/FA 3/15/22 Akoya Biosciences, Inc. 10-K 12/31/21 92:10M Toppan Merrill Bridge/FA 4/12/21 Akoya Biosciences, Inc. S-1/A 8:6.1M Toppan Merrill/FA 3/26/21 Akoya Biosciences, Inc. S-1 21:8M Toppan Merrill/FA |